Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Fate Therapeutics Q1 EPS $(0.32) Beats $(0.38) Estimate, Sales $1.63M Beat $1.14M Estimate

Author: Benzinga Newsdesk | May 13, 2025 03:12pm
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.38) by 15.79 percent. This is a 31.91 percent increase over losses of $(0.47) per share from the same period last year. The company reported quarterly sales of $1.63 million which beat the analyst consensus estimate of $1.14 million by 42.69 percent. This is a 15.38 percent decrease over sales of $1.93 million the same period last year.

Posted In: FATE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist